EMPOWER™ モジュール式ペーシング システムと EMBLEM™ 皮下 ICD による抗頻脈ペーシングの伝達の有効性 (MODULAR ATP)
The MODULAR ATP Clinical Study is designed to demonstrate safety, performance, and effectiveness of the Modular Cardiac Rhythm Management (mCRM) Therapy System.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The MODULAR ATP Clinical Study will enroll subjects with a standard Implantable Cardioverter Defibrillator (ICD) indication applying international practice guidelines, as well as those who already have an implanted S-ICD System and satisfy the inclusion criteria for this study, while not meeting any exclusion criteria. Subjects will be followed for at least 6 months following mCRM Therapy System implantation.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Banner University Medical Center Phoenix
-
Scottsdale、Arizona、アメリカ、84258
- Scottsdale Healthcare - Shea
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- Arrhythmia Research Group
-
-
Florida
-
Orlando、Florida、アメリカ、32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- Emory University Hospital
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health Lexington
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
New Jersey
-
Camden、New Jersey、アメリカ、08103
- Cooper Hospital - University Medical Center
-
-
New York
-
Manhasset、New York、アメリカ、11030
- Northwell University Hospital
-
New York、New York、アメリカ、10029
- Mount Sinai Medical Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Medical Center
-
Columbus、Ohio、アメリカ、43214
- Ohio Health Research Institute
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- Penn State Health Milton S. Hershey Medical Center
-
Philadelphia、Pennsylvania、アメリカ、19104
- Hospital of the University of Pennsylvania
-
-
Tennessee
-
Chattanooga、Tennessee、アメリカ、37403
- Erlanger Medical Center
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23507
- Sentara Norfolk General
-
-
Washington
-
Seattle、Washington、アメリカ、98195
- University of Washington Medical Center
-
-
-
-
-
Leeds、イギリス、LS1 EX
- The General Infirmary
-
Liverpool、イギリス、L14 3PE
- Liverpool Heart and Chest Hospital
-
Manchester、イギリス、M13 9WL
- Manchester Heart Center
-
Southampton、イギリス
- Southampton University Hospital
-
-
-
-
-
Brescia、イタリア
- Spedali Civil di Brescia
-
Cotignola、イタリア
- Maria Cecilia Hospital SPA
-
Naples、イタリア、80131
- AZ Osp Monaldi
-
Pisa、イタリア、56126
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
-
Amsterdam、オランダ
- Amsterdam University Medical Center
-
Nieuwegein、オランダ
- St. Antonius Ziekenhuis
-
Rotterdam、オランダ、3015 CE
- Erasmus MC University Medical Center
-
-
-
-
-
Linz、オーストリア
- Kepler Universitaetsklinikum
-
-
-
-
-
Québec、カナダ
- Institut Universitaire de Cardilogie et Pnuemologie de Quebec (IUCPQ)
-
-
Quebec
-
Montreal、Quebec、カナダ、H1T 1C8
- Institut de Cardiologie de Quebec (Montreal Heart)
-
-
-
-
-
Barcelona、スペイン、08036
- Hospital Clinic of Barcelona
-
-
-
-
-
Prague、チェコ
- Na Homolce Hospital
-
-
-
-
-
Grenoble、フランス
- CHU Grenoble - Hospital Michallon
-
Lille、フランス、59000
- CHRU de Lille
-
Nantes、フランス
- CHU de Nantes-Hopital Laennec
-
Paris、フランス
- Hospital European Georges-Pompidou
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patient who meets Class I, IIa, or IIb guideline ICD indications[i],[ii], or who has an existing TV-ICD[iii] or S-ICD[iv]
-
Patient who is deemed to be at risk for MVT based on at least ONE of the following:
- History of Non-Sustained MVT with LVEF ≤ 50%
- History of sustained VT/VF (secondary prevention) with LVEF ≤ 50% or significant cardiac scar*
- History of syncope deemed to be arrhythmic in origin
- History of ischemic cardiomyopathy with LVEF ≤35%
- History of non-ischemic cardiomyopathy with LVEF ≤35% and significant scar*
-
Patient who is willing and capable of providing informed consent (which is not to include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing associated with this investigation at an approved study site and at the intervals defined by this protocol
-
Patient who is age 18 years or above, or of legal age to give informed consent specific to state and national law
Exclusion Criteria:
-
Patient with an ongoing complication due to Cardiac Implantable Electronic Device (CIED) infection or CIED explant
-
Transvenous lead remnants within the heart from a previously implanted CIED (Note: transvenous lead remnants outside the heart (e.g., in the SVC) are allowed)
-
Patient with a known LA thrombus
-
Patient with a ventricular arrhythmia due to a reversible cause
-
Patient indicated for implantation of a dual chamber pacemaker or cardiac resynchronization therapy (CRT)
-
Patient with another implanted medical device that could interfere with implant of the leadless pacemaker, such as an implanted inferior vena cava filter or mechanical tricuspid heart valve
-
Patient requires rate-responsive pacing therapy
-
Patient is entirely pacemaker-dependent (defined as escape rhythm ≤ 30 bpm)
-
Patient with Acute Coronary Syndrome (i.e. Acute Myocardial Infarction, Unstable Angina) within 40 days
-
Inability to access femoral vein with a 21-French or larger inner diameter introducer sheath due to known anatomy condition, recent surgery, and/ or other relevant condition
-
Patient who has an active implanted electronic medical device intended for chronic use concomitantly with the study system, such as a left ventricular assist device (LVAD). Note that a temporary pacing wire is allowed.
-
Patient with known or suspected sensitivity to Dexamethasone Acetate (DXA)
-
Patient with a known cardiovascular anatomy that precludes implant in the right ventricle
-
Patient with a known allergy to any system components
-
Patient with a known or suspected intolerance to S-ICD conversion testing, based on physician discretion
-
Patient is not likely to have meaningful survival** for at least 12 months (documented or per investigator's discretion)
-
Patient is enrolled in any other concurrent study. Co-enrollment into other studies such as observational studies/ registries needs prior written approval by BSC. Local mandatory governmental registries are accepted for co-enrollment without approval by BSC.
-
Patient who is a woman of childbearing potential who is known to be pregnant at the time of study enrollment (method of assessment upon investigator's discretion)
[i]Al-Khatib, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. (2018); 138:e272-e391.
[ii] 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). European Heart Journal (2015) 36, 2793-2867.
[iii] TV-ICD system is expected to be fully explanted during or prior to full Coordinated System implant
[iv] Potential subjects with a Model 1010 S-ICD Pulse Generator are only eligible for MODULAR ATP if they are getting upgraded to Model A209, A219 or future BSC S-ICD Pulse Generator; Patients with an existing S-ICD PG subject to the electrical overstress field action are only eligible for MODULAR ATP if they are getting a new BSC Model A209 or A219, or future BSC S-ICD Pulse Generator
*Significant cardiac scar is defined as a scar involving at least one ventricular myocardial segment (i.e., basal infero-septum) as identified in the official findings of a cMRI, or nuclear viability study, or echo report by the interpreting radiologist/ cardiologist who is not affiliated with the study
**meaningful survival means that a patient has a reasonable quality of life and functional status
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:MODULAR ATP Study Participants
All subjects that signed the informed consent were included. Patients consented to receive the mCRM Therapy System which consists of the EMPOWER Leadless Pacemaker and an EMBLEM S-ICD upgraded with investigational firmware. |
Communication testing between S-ICD and LCP in 4 body postures as well as required electrical testing.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Safety Endpoint 1: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 6 Months
時間枠:Implant through 6 Months Post-Implant
|
Major EMPOWER MPS System- and Procedure-related Complication-Free Rate Subjects will be assessed for safety issues related to the procedure or system through 6 months post implant |
Implant through 6 Months Post-Implant
|
|
Safety Endpoint 2: Percentage of Subjects Without Major EMPOWER MPS System- or Procedure-Related Complications Through 12 Months
時間枠:Implant through 12 Months Post-Implant
|
Major EMPOWER MPS System- and Procedure-related Complication-free Rate Subjects will be assessed for safety issues related to the procedure or system through 12 months post implant |
Implant through 12 Months Post-Implant
|
|
Primary Effectiveness Endpoint 1: Percentage of Body Postures With Communication Success Between the S-ICD and EMPOWER PG
時間枠:At the 6 Month Follow-up
|
Communication Success between the S-ICD and EMPOWER PG Data from subjects will be assessed for effectiveness of communication between S-ICD and the EMPOWER PG by evaluating if a paced beat is present during communication testing in four postures: upright, supine, and right and left side. |
At the 6 Month Follow-up
|
|
Primary Effectiveness Endpoint 2: Percentage of Subjects Classified as a Pacing Capture Threshold (PCT) Responder
時間枠:At the 6 Month Follow-up
|
Proportion of Subjects with Adequate Pacing Capture Threshold Effectiveness will be confirmed by evaluating the percentage of subjects considered to be a PCT Responder, defined as a subject with a PCT measurement of ≤ 2.0 V @ 0.4 ms pulse width |
At the 6 Month Follow-up
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary Effectiveness Endpoint: Subject-specific Slope of EMPOWER PG Sensor-Indicated Rate to the Subject's Workload on Treadmill Test
時間枠:At the 3 Month Visit
|
Metabolic-Chronotropic Relation Slope (MCR Slope) from the Kay-Wilkoff Model Using the Kay-Wilkoff model, data will be assessed to evaluate the proportionality of the EMPOWER PG's sensor-indicated rate to the subject's workload during the treadmill test |
At the 3 Month Visit
|
|
Secondary Safety Endpoint
時間枠:Implant through 2 years post-implant
|
All-Cause Survival; data not reported as it is still being collected |
Implant through 2 years post-implant
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Reinoud Knops, MD, PhD、Amsterdam University Medical Centre
- 主任研究者:Lluis Mont, MD, PhD、Hospital Clinic, University of Barcelona
- 主任研究者:Vivek Reddy, MD、The Mount Sinai Hospital
- 主任研究者:Michael Lloyd, MD、Emory University
出版物と役立つリンク
一般刊行物
- Lloyd MS, Brisben AJ, Reddy VY, Blomstrom-Lundqvist C, Boersma LVA, Bongiorni MG, Burke MC, Cantillon DJ, Doshi R, Friedman PA, Gras D, Kutalek SP, Neuzil P, Roberts PR, Wright DJ, Appl U, West J, Carter N, Stein KM, Mont L, Knops RE. Design and rationale of the MODULAR ATP global clinical trial: A novel intercommunicative leadless pacing system and the subcutaneous implantable cardioverter-defibrillator. Heart Rhythm O2. 2023 Jun 2;4(7):448-456. doi: 10.1016/j.hroo.2023.05.004. eCollection 2023 Jul.
- Knops RE, Lloyd MS, Roberts PR, Wright DJ, Boersma LVA, Doshi R, Friedman PA, Neuzil P, Blomstrom-Lundqvist C, Bongiorni MG, Burke MC, Gras D, Kutalek SP, Amin AK, Fu EY, Epstein LM, Tolosana JM, Callahan TD, Aasbo JD, Augostini R, Manyam H, Nair DG, Mondesert B, Su WW, Pepper C, Miller MA, Grammes J, Saleh K, Marquie C, Merchant FM, Cha YM, Cunnington C, Frankel DS, West J, Matznick E, Swackhamer B, Brisben AJ, Weinstock J, Stein KM, Reddy VY, Mont L; MODULAR ATP Investigators. A Modular Communicative Leadless Pacing-Defibrillator System. N Engl J Med. 2024 Oct 17;391(15):1402-1412. doi: 10.1056/NEJMoa2401807. Epub 2024 May 18.
- Lloyd MS, Reddy VY, Roberts P, Doshi RN, Wright DL, Boersma LVA, Friedman PA, Neuzil P, Blomstrom-Lundqvist C, Bongiorni MG, Burke MC, Gras D, Kutalek SP, Marijon E, Tolosana JM, Amin AK, Epstein LM, Aasbo JD, Callahan TD, Brisben AJ, West J, Matznick E, Speakman B, Bachman TN, Mont L, Knops RE. One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator. Circ Arrhythm Electrophysiol. 2026 Jan;19(1):e014395. doi: 10.1161/CIRCEP.125.014395. Epub 2025 Nov 13.
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- C1907
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
There is no plan to share IPD with other researchers in this study.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。